12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Opsumit macitentan: Phase II discontinued

Actelion said an IDMC recommended terminating the double-blind, placebo-controlled, international Phase III DUAL-2 trial of once-daily oral macitentan after determining additional data are "unlikely to result in a positive primary outcome measure." The IDMC also said there were no unexpected safety findings in the trial. Actelion is evaluating 3 and 10 mg macitentan...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >